Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity

被引:80
作者
Menegola, E
Di Renzo, F
Broccia, ML
Prudenziati, M
Minucci, S
Massa, V
Giavini, E
机构
[1] Univ Milan, Dept Biol, I-20133 Milan, Italy
[2] Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy
关键词
HDAC inhibitors; malformations; mouse; VPA; TSA; hyperacetylation; somite; neural tube;
D O I
10.1002/bdrb.20053
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: the inhibition of histone deacetylase (HDAC) has been reported as an effective mechanism on therapy in neoplastic diseases. Among HDAC inhibitors, Trichostatin A (TSA) and Valproic Acid (VPA) prevent the tumorigenesis in rodent and human models. Malformations as neural tube and axial skeletal defects are well-known VPA side effects. Recent hypotheses suggest the HDAC inhibitor activity as the teratogenic mechanism of VPA. The teratogenic potency of TSA is, at the moment, unknown. The aim of the present work is to investigate the HDAC inhibition on embryos exposed in utero to TSA or VPA and to compare the teratogenic potential of these two molecules on the axial skeleton morphogenesis. METHODS: Pregnant CD mice were i.p. treated on day 8 post coitum (9.00 a.m.) with 400 mg/kg VPA or with 0, 2, 4, 8, 16 mg/kg TSA. Embryos explanted 1 hr after the treatment from some females exposed to 400 mg/kg VPA or to 16 mg/kg TSA were processed for Western blotting and immunohistochemical analysis, in order to evaluate the histone hyperacetylation in the total embryo homogenates and to visualize the hyperacetylated tissues. Foetuses at term were processed for skeletal examination. RESULTS: Both VPA and TSA were able to induce hyperacetylation on embryos, specifically at the level of the caudal neural tube and of somites. At term, TSA showed teratogenic effects at the axial skeleton, quite similar to those observed after VPA exposure. CONCLUSIONS: In conclusion, both VPA and TSA are teratogenic in mice. A direct correlation between somite hyperacetylation and axial abnormalities could suggest the HDAC inhibition as the mechanism of the teratogenic effects.
引用
收藏
页码:392 / 398
页数:7
相关论文
共 26 条
[1]   Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells [J].
Chiba, T ;
Yokosuka, O ;
Fukai, K ;
Kojima, H ;
Tada, M ;
Arai, M ;
Imazeki, F ;
Saisho, H .
ONCOLOGY, 2004, 66 (06) :481-491
[2]   Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein [J].
David, G ;
Alland, L ;
Hong, SH ;
Wong, CW ;
DePinho, RA ;
Dejean, A .
ONCOGENE, 1998, 16 (19) :2549-2556
[3]   MARKED ACCUMULATION OF VALPROIC ACID IN EMBRYONIC NEUROEPITHELIUM OF THE MOUSE DURING EARLY ORGANOGENESIS [J].
DENCKER, L ;
NAU, H ;
DARGY, R .
TERATOLOGY, 1990, 41 (06) :699-706
[4]  
EIKEL D, 2004, REPROD TOXICOL, V18, P707
[5]   Mechanisms of action of valproate: a commentatory [J].
Johannessen, CU .
NEUROCHEMISTRY INTERNATIONAL, 2000, 37 (2-3) :103-110
[6]   Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer [J].
Johnstone, RW .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :287-299
[7]   Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy [J].
Kosugi, H ;
Towatari, M ;
Hatano, S ;
Kitamura, K ;
Kiyoi, H ;
Kinoshita, T ;
Tanimoto, M ;
Murate, T ;
Kawashima, K ;
Saito, H ;
Naoe, T .
LEUKEMIA, 1999, 13 (09) :1316-1324
[8]   New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro:: Activation of the peroxisomal proliferator-activated receptor (PPARδ) [J].
Lampen, A ;
Siehler, S ;
Ellerbeck, U ;
Göttlicher, M ;
Nau, H .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1999, 160 (03) :238-249
[9]   Transcriptional regulation in acute promyelocytic leukemia [J].
Lin, RJ ;
Sternsdorf, T ;
Tini, M ;
Evans, RM .
ONCOGENE, 2001, 20 (49) :7204-7215
[10]  
Menegola E, 1996, TERATOGEN CARCIN MUT, V16, P97, DOI 10.1002/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.3.CO